Physician profile
Sunil Shivaram
NPI 1942393566
$4,001.52
in general payments reported to CMS, 2019-2025
27 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $103 · 2021: $559 · 2022: $150 · 2023: $242 · 2024: $403 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431 · Entertainment: $17.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.69 |
| Entertainment | $17.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,000.00 | 2019 | |
| Alcon Vision LLC | $601.78 | 2019-2025 | Rocklatan, Clareon, Tryptyr |
| Smith+Nephew, INC. | $516.52 | 2021 | |
| Bausch & Lomb Americas INC. | $290.96 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Amgen INC. | $228.04 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $196.18 | 2019 | |
| Rxsight INC | $155.74 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $142.77 | 2019-2020 | |
| Abbvie INC. | $108.20 | 2023-2024 | Xen Glaucoma Treatment System |
| Harrow Eye, LLC | $99.28 | 2024-2025 | Iheezo, Vevye |
| Dompe US, INC. | $68.62 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $63.68 | 2019-2020 | |
| Allergan, INC. | $61.16 | 2019 | |
| Horizon Therapeutics Plc | $56.09 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.72 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $47.35 | 2019-2023 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $44.23 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $37.70 | 2019 | |
| Aerie Pharmaceuticals, INC. | $37.60 | 2019 | |
| Nova Eye, INC. | $34.71 | 2024 | |
| Astellas Pharma US INC | $33.16 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $27.03 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $22.70 | 2019 | |
| Thea Pharma INC. | $21.53 | 2024 | Iyuzeh |
| Oyster Point Pharma, INC. | $20.17 | 2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $17.20 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Shivaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.